LY-2300559

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H26O6
Molecular Weight	434.481
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCCC1=C(OCC2=CC=C(C=C2)[C@H](O)C3=CC(=CC=C3)C(O)=O)C=CC(C(C)=O)=C1O

InChI

InChIKey=DWQVYDLTPMGYNE-DEOSSOPVSA-N

InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H26O6
Molecular Weight	434.481
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

LY2300559 is a dual metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. Eli Lilly was developing LY2300559 for the prevention of migraine. LY2300559 development has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Metabotropic glutamate receptor 2 24	Positive Allosteric Modulator 179		50.0 nM [EC50]
Cysteinyl leukotriene receptor 1 20	Antagonist 2,778		22.0 nM [Ki]

PubMed

PubMed

Title	Date	PubMed
No data available in table

Sample Use Guides

In Vivo Use Guide

Phase 2 study in migraine prevention: 300 mg once daily, for 12 weeks

Route of Administration: Oral

Substance Class	Chemical
Record UNII	Z572ZBT8XL
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

LY-2300559

Common Name

English

LY2300559

Code

English

3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYL-PHENOXY)METHYL)PHENYL)-HYDROXY-METHYL)BENZOIC ACID

Systematic Name

English

BENZOIC ACID, 3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)METHYL)PHENYL)HYDROXYMETHYL)-

Systematic Name

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

Z572ZBT8XL

PRIMARY

CAS

889116-06-7

PRIMARY

CLINICAL_TRIALS.GOV

LY-2300559

PRIMARY

Official Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine

PUBCHEM

11611800

PRIMARY

DRUG BANK

DB13016

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					Z572ZBT8XL

LY-2300559

ACTIVE MOIETY

Comments:

Class: Antimigraine; Mechanism of Action: Leukotriene D4 receptor antagonist, Metabotropic glutamate receptor 2 modulator; Highest Development Phase: Discontinued for Migraine; Most Recent Events: 16 Jul 2012 Discontinued - Phase-II for Migraine in Puerto Rico (PO), 16 Jul 2012 Discontinued - Phase-II for Migraine in USA (PO), 01 Apr 2012 Eli Lilly completes a phase II trial for Migraine prevention in USA and Puerto Rico (NCT01184508)

Showing 1 to 1 of 1 entries

Previous1Next